SCHEMBL5888974

SCHEMBL5888974

Clc1nc(Cl)nc(SCc2ccccc2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
NPC1 O15118 2/20 0.59
HSD17B10 Q99714 1/20 0.57
HSP90AA1 P07900 1/20 0.53
CTSB P07858 3/20 0.51
ALDH1A1 P00352 2/20 0.51
CYP1A2 P05177 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
PAK4 O96013 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
CYP2C19 P33261 1/20 0.51
PPARG P37231 1/20 0.51
HTT P42858 1/20 0.51
NCOA2 Q15596 1/20 0.51
NCOA1 Q15788 1/20 0.51
ALOX15 P16050 1/20 0.50
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2850225 0.88 HSP90AA1 (0.67) RAB9ASMN1; SMN2NPC1HSD17B10HSP90AA1
SCHEMBL13752162 0.85 RAB9A (0.70) RAB9ASMN1; SMN2NPC1HSD17B10HSP90AA1
SCHEMBL17558052 0.84 MEN1 (0.66) RAB9ASMN1; SMN2NPC1HSP90AA1CTSB
SCHEMBL13631436 0.84 RAB9A (0.51) RAB9ASMN1; SMN2NPC1HSD17B10HSP90AA1
SCHEMBL489903 0.82 RAB9A (0.62) RAB9ASMN1; SMN2NPC1HSD17B10HSP90AA1
SCHEMBL28853540 0.79 RAB9A (0.64) RAB9ASMN1; SMN2NPC1HSD17B10HSP90AA1
SCHEMBL9874270 0.78 HSD17B10 (0.46) RAB9ASMN1; SMN2NPC1HSD17B10HSP90AA1
SCHEMBL6335734 0.78 AR (0.48) MAPT
Ammonia Solution, Strong SCHEMBL20610130 0.77 RAB9A (0.59) RAB9ASMN1; SMN2NPC1HSD17B10HSP90AA1
SCHEMBL15386230 0.77 ALDH1A1 (0.69) RAB9ASMN1; SMN2HSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851529-B2 Triazine ring-containing polymer, and thermoplastic article and optical part including same SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-12-26 US disclosed
US-20200362112-A1 TRIAZINE RING-CONTAINING POLYMER, AND THERMOPLASTIC ARTICLE AND OPTICAL PART INCLUDING SAME NATIONAL UNIVERSITY CORPORATION IWATE UNIVERSITY (JP) 2020-11-19 US disclosed
US-7115737-B2 Solid phase synthesis of novel biaryl triazine library by suzuki cross coupling NEW YORK UNIVERSITY (US) 2006-10-03 US disclosed
US-20040225125-A1 Solid phase synthesis of novel biaryl triazine library by suzuki cross coupling NEW YORK UNIVERSITY (US) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040225125-A1 Solid phase synthesis of novel biaryl triazine library by suzuki cross coupling BOLA2; BOLA2B, BRDT, SBDS RAB9A 3618/4885SMN1; SMN2 3731/4885NPC1 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.